Researchers at the University of Colorado Anschutz Medical Campus have uncovered a critical, previously underappreciated role ...

The new plasma B-cell service is projected to be of particular value to clients pursuing difficult targets in antibody discovery, enabling them to leverage new processes and technologies while ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

The following is a summary of “Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab,” published in the April 2025 issue of Journal of ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ranging from ...

Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that for the first time, single plasma B-cell discovery services will be part of the company’s ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...